Psilocybin Clinical Trials in New York: 2026 Recruiting List

Where things stand

ClinicalTrials.gov lists 30 interventional studies that give psilocybin or a close relative of it and have at least one site in New York State. Of those, 12 are recruiting at a New York site now, 4 haven't started recruiting, and 10 are finished.¹ Outside a registered study, possessing any amount of psilocybin in New York is a crime under Penal Law 220.03.¹⁵

Two things to know before you read the list. First, 6 of the 30 studies don't give psilocybin. They test CYB003, which the registry calls "a deuterated psilocin analog," or RE104, a prodrug of 4-OH-DiPT, a synthetic psychedelic similar in structure to psilocin.³ We mark each one "psilocybin-like compound"; the "Psilocybin only" filter hides them. Second, each record's enrollment figure is the whole trial's total across every site, not the number of New Yorkers taking part: an actual count for finished trials, a target for open ones.¹

Every psilocybin trial with a New York site

Recruiting studies come first. Tap one for its sponsor, phase, ages and a link to its registry record, which has the contact details. "Recruiting elsewhere, not at the New York site" means the trial is open, but not here.

30 trials.

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD RecruitingSubstance use NYU Langone Health, New York Details

Study
NCT06349083 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2
Drug studied
psilocybin
Enrollment
200 people (anticipated)
Ages
18 to 65
Start
September 1, 2026
Primary completion
May 2030
Psilocybin-Assisted Therapy for Intergenerational Trauma RecruitingPTSD and trauma The Parsons Research Center for Psychedelic Healing, New York Details

Study
NCT06899165 on ClinicalTrials.gov

Sponsor
Rachel Yehuda

Phase
Phase 2
Drug studied
psilocybin
Enrollment
100 people (anticipated)
Ages
18 and older
Start
August 28, 2026
Primary completion
May 31, 2029
Psilocybin to Treat Depression in Spinal Cord Injury RecruitingDepression James J. Peters Department of Veterans Affairs Medical Center, The Bronx Details

Study
NCT07251491 on ClinicalTrials.gov

Sponsor
James J. Peters Veterans Affairs Medical Center

Phase
Phase 1/Phase 2
Drug studied
psilocybin
Enrollment
30 people (anticipated)
Ages
22 and older
Start
August 6, 2026
Primary completion
March 1, 2028
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults RecruitingOther conditions New York University Langone Health, Center for Psychedelic Medicine, New York Details

Study
NCT07516405 on ClinicalTrials.gov

Sponsor
University of Colorado, Denver

Phase
Phase 1
Drug studied
psilocybin
Enrollment
40 people (anticipated)
Ages
65 to 85
Start
April 1, 2026
Primary completion
March 2028
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder RecruitingPTSD and trauma NY, New York; NY, The Bronx Details

Study
NCT07570654 on ClinicalTrials.gov

Sponsor
COMPASS Pathways

Phase
Phase 2/Phase 3
Drug studied
psilocybin (COMP360)
Enrollment
300 people (anticipated)
Ages
18 and older
Start
September 2026
Primary completion
November 2028
Psilocybin as a Novel Therapy for Residual Anhedonia RecruitingDepression NYU Langone Health, New York Details

Study
NCT07607938 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 1
Drug studied
psilocybin
Enrollment
90 people (anticipated)
Ages
18 to 65
Start
September 2026
Primary completion
August 1, 2030
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder RecruitingDepression Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York Details

Study
NCT06592833 on ClinicalTrials.gov

Sponsor
Icahn School of Medicine at Mount Sinai

Phase
Phase 2
Drug studied
psilocybin (alone vs with pimavanserin)
Enrollment
60 people (anticipated)
Ages
21 to 80
Start
February 25, 2025
Primary completion
March 1, 2028
Psilocybin for Opioid Use Disorder (OUD) RecruitingSubstance use StartCare, Brooklyn; NYU Langone Health, New York; VIP Community Services, Inc, The Bronx Details

Study
NCT06796062 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2
Drug studied
psilocybin
Enrollment
480 people (anticipated)
Ages
18 to 65
Start
December 17, 2025
Primary completion
February 2029
Psilocybin Therapy in Advanced Cancer RecruitingCancer distress or pain NYU Langone Health, New York Details

Study
NCT05398484 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2/Phase 3
Drug studied
psilocybin
Enrollment
200 people (anticipated)
Ages
21 to 100
Start
May 24, 2023
Primary completion
January 1, 2027
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder RecruitingAnxiety, psilocybin-like compound NYU-H+C Clinical and Translational Science Institute, New York Details

Study
NCT07489651 on ClinicalTrials.gov

Sponsor
Reunion Neuroscience Inc

Phase
Phase 2
Drug studied
RE104 (prodrug of 4-OH-DiPT, a psilocin analog)
Enrollment
160 people (anticipated)
Ages
18 to 74
Start
April 20, 2026
Primary completion
July 2027
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder RecruitingDepression, psilocybin-like compound Adams Clinical Harlem, New York; New York State Psychiatric Institute, New York; Adams Clinical Bronx, The Bronx Details

Study
NCT06793397 on ClinicalTrials.gov

Sponsor
Cybin IRL Limited

Phase
Phase 3
Drug studied
CYB003 (deuterated psilocin analog)
Enrollment
330 people (anticipated)
Ages
18 to 85
Start
December 10, 2025
Primary completion
June 7, 2027
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses RecruitingCancer distress or pain, psilocybin-like compound Roswell Park Center Institute, Buffalo; NYU Langone Health, New York Details

Study
NCT07002034 on ClinicalTrials.gov

Sponsor
Reunion Neuroscience Inc

Phase
Phase 2
Drug studied
RE104 (prodrug of 4-OH-DiPT, a psilocin analog)
Enrollment
100 people (anticipated)
Ages
18 to 80
Start
July 30, 2025
Primary completion
November 2026
Psilocybin FCR Early-Stage Breast Cancer Not yet recruitingCancer distress or pain NYU Langone Heath, New York Details

Study
NCT07909408 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2
Drug studied
psilocybin
Enrollment
100 people (anticipated)
Ages
21 and older
Start
January 2, 2027
Primary completion
January 2, 2031
Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) Not yet recruitingOther conditions NYU Langone Health, New York Details

Study
NCT06760533 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Early Phase 1
Drug studied
psilocybin
Enrollment
10 people (anticipated)
Ages
18 to 75
Start
August 2026
Primary completion
December 2026
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids Not yet recruitingCancer distress or pain Roswell Park Cancer Institute, Buffalo Details

Study
NCT06827054 on ClinicalTrials.gov

Sponsor
Roswell Park Cancer Institute

Phase
Phase 2
Drug studied
psilocybin
Enrollment
20 people (anticipated)
Ages
18 to 75
Start
September 15, 2026
Primary completion
May 5, 2027
Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter Not yet recruitingOther conditions NYU Langone Health, New York Details

Study
NCT07296328 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2
Drug studied
psilocybin
Enrollment
25 people (anticipated)
Ages
18 to 50
Start
January 15, 2026
Primary completion
April 1, 2027
Psilocybin for Major Depressive Disorder (MDD) Active, not recruitingDepression NYU Clinical & Translational Science Institute, New York; Bronx Veterans Research Foundation at the James J. Peters VAMC, The Bronx Details

Study
NCT06308653 on ClinicalTrials.gov

Sponsor
Usona Institute

Phase
Phase 3
Drug studied
psilocybin
Enrollment
238 people (actual)
Ages
18 and older
Start
March 13, 2024
Primary completion
January 5, 2026
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder Recruiting elsewhere, not at the New York siteSubstance use New York University, New York Details

Study
NCT05452772 on ClinicalTrials.gov

Sponsor
Johns Hopkins University

Phase
Phase 2
Drug studied
psilocybin
Enrollment
66 people (anticipated)
Ages
21 and older
Start
November 1, 2023
Primary completion
December 2026
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD Active, not recruitingDepression Dent Neurosciences Research Center, Inc., Amherst; Fieve Clinical Research, Inc, New York; Spectrum Neuroscience and Treatment Institute, New York; Adams Clinical - New York, New York; New York State Psychiatric Institute, New York; Richmond Behavioral Associates, Staten Island; Adams Clinical - New York, The Bronx Details

Study
NCT05711940 on ClinicalTrials.gov

Sponsor
COMPASS Pathways

Phase
Phase 3
Drug studied
psilocybin (COMP360)
Enrollment
572 people (actual)
Ages
18 and older
Start
February 14, 2023
Primary completion
November 13, 2025
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) Enrolling by invitationDepression, psilocybin-like compound Adams Clinical Harlem, New York; Adams Clinical Bronx, The Bronx Details

Study
NCT06605105 on ClinicalTrials.gov

Sponsor
Cybin IRL Limited

Phase
Phase 3
Drug studied
CYB003 (deuterated psilocin analog)
Enrollment
468 people (anticipated)
Ages
18 to 85
Start
July 18, 2025
Primary completion
June 6, 2028
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD CompletedDepression New York State Psychiatric Institute, New York; The Medical Research Network, LLC, New York Details

Study
NCT05624268 on ClinicalTrials.gov

Sponsor
COMPASS Pathways

Phase
Phase 3
Drug studied
psilocybin (COMP360)
Enrollment
258 people (actual)
Ages
18 and older
Start
January 24, 2023
Primary completion
May 28, 2025
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder CompletedPTSD and trauma Icahn School of Medicine at Mount Sinai, New York Details

Study
NCT05312151 on ClinicalTrials.gov

Sponsor
COMPASS Pathways

Phase
Phase 2
Drug studied
psilocybin (COMP360)
Enrollment
22 people (actual)
Ages
18 and older
Start
June 10, 2022
Primary completion
February 12, 2024
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder CompletedOther conditions New York State Psychiatric Institute, 1051 Riverside Drive, New York Details

Study
NCT04656301 on ClinicalTrials.gov

Sponsor
New York State Psychiatric Institute

Phase
Phase 2
Drug studied
psilocybin
Enrollment
12 people (actual)
Ages
18 to 55
Start
February 26, 2021
Primary completion
November 2, 2022
A Study of Psilocybin for Major Depressive Disorder (MDD) CompletedDepression New York University School of Medicine, New York Details

Study
NCT03866174 on ClinicalTrials.gov

Sponsor
Usona Institute

Phase
Phase 2
Drug studied
psilocybin
Enrollment
347 people (actual)
Ages
21 to 65
Start
January 23, 2020
Primary completion
June 28, 2022
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression CompletedDepression New York State Psychiatric Institute, New York Details

Study
NCT03775200 on ClinicalTrials.gov

Sponsor
COMPASS Pathways

Phase
Phase 2
Drug studied
psilocybin (COMP360)
Enrollment
233 people (actual)
Ages
18 and older
Start
March 1, 2019
Primary completion
July 30, 2021
The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals CompletedOther conditions NYU Langone Medical Center/Tisch Hospital, New York Details

Study
NCT02421263 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 1
Drug studied
psilocybin
Enrollment
12 people (actual)
Ages
25 to 76
Start
April 2015
Primary completion
June 5, 2020
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence CompletedSubstance use Clinical and Translational Science Institute, NYU Langone Medical Center, New York Details

Study
NCT02061293 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Phase 2
Drug studied
psilocybin
Enrollment
95 people (actual)
Ages
25 to 65
Start
June 2014
Primary completion
July 30, 2021
Psilocybin Cancer Anxiety Study CompletedCancer distress or pain NYU College of Dentistry Bluestone Center for Clinical Research, New York Details

Study
NCT00957359 on ClinicalTrials.gov

Sponsor
NYU Langone Health

Phase
Early Phase 1
Drug studied
psilocybin
Enrollment
29 people (actual)
Ages
18 to 76
Start
February 2009
Primary completion
September 6, 2018
RE104 Safety and Efficacy Study in Postpartum Depression CompletedDepression, psilocybin-like compound Reunion Investigational Site, Buffalo; Reunion Investigational Site, New York; Reunion Investigational Site, New York Details

Study
NCT06342310 on ClinicalTrials.gov

Sponsor
Reunion Neuroscience Inc

Phase
Phase 2
Drug studied
RE104 (prodrug of 4-OH-DiPT, a psilocin analog)
Enrollment
84 people (actual)
Ages
18 to 45
Start
June 14, 2024
Primary completion
May 22, 2025
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder CompletedDepression, psilocybin-like compound Adams Clinical Harlem, New York; Adams Clinical Bronx, The Bronx Details

Study
NCT06564818 on ClinicalTrials.gov

Sponsor
Cybin IRL Limited

Phase
Phase 3
Drug studied
CYB003 (deuterated psilocin analog)
Enrollment
223 people (actual)
Ages
18 to 85
Start
December 17, 2024
Primary completion
September 4, 2026

Download this data. Psilocybin clinical trials with a site in New York State: CSV (20 KB) or JSON (36 KB), 30 rows, updated November 3, 2026.

Free to reuse under CC BY 4.0. Please credit Mushrooms New York and link to this page.

Where the trials are: NYU Langone, Mount Sinai, Columbia and the Bronx VA

Most sites are in Manhattan and the Bronx, with a few in Brooklyn, Staten Island and the Buffalo area. A study can list several sites, so the counts overlap.¹

New York sites and the studies open at each, as of November 2, 2026
Site	Studies on the list	Recruiting at this site now
NYU Langone Health, Manhattan	16	Advanced cancer (NCT05398484), alcohol use disorder (NCT06349083), opioid use disorder (NCT06796062), residual anhedonia (NCT07607938), healthy adults 65 to 85 (NCT07516405), and RE104 for anxiety (NCT07489651) and for adjustment disorder in cancer (NCT07002034)
Mount Sinai, Manhattan	3	Major depression, psilocybin with or without pimavanserin (NCT06592833), and intergenerational trauma (NCT06899165)
New York State Psychiatric Institute and Columbia, Washington Heights	5	None; its site on the CYB003 depression trial is listed as not yet recruiting
James J. Peters VA Medical Center, the Bronx	2	Depression in veterans with spinal cord injury (NCT07251491)
Adams Clinical, Harlem and the Bronx	4	CYB003 for major depression (NCT06793397)
Roswell Park Comprehensive Cancer Center, Buffalo	2	RE104 for adjustment disorder (NCT07002034)

NYU's opioid study also runs at StartCare in Brooklyn and VIP Community Services in the Bronx, and Compass Pathways' PTSD trial (NCT07570654) is recruiting at sites the registry lists only as "NY" in Manhattan and the Bronx.² NYU Langone opened its Center for Psychedelic Medicine in February 2021.⁴ Mount Sinai's center, launched in January 2021 and now the Parsons Research Center for Psychedelic Healing, expanded into a new facility at 600 West 112th Street in 2024.⁵ Columbia's Depression Evaluation Service says it has "several studies in development" with psychedelics.⁶

Landmark psilocybin studies run in New York

New York sites helped produce several of the results that put psilocybin into late-stage trials. Each finding is from the published paper, not advice.

Published psilocybin studies with a New York site
Study	New York role	What it found
Cancer-related anxiety and depression, J Psychopharmacol 2016 (PMID 27909164)	Run at NYU	In 29 patients, 83% of the psilocybin-first group had an antidepressant response at seven weeks, against 14% of the niacin-first group. About 4.5 years later, 60% to 80% of the 15 followed up met criteria for a clinically significant response.⁷
Alcohol use disorder, JAMA Psychiatry 2022 (PMID 36001306)	Led by NYU	Among 95 adults, heavy-drinking days over 32 weeks were 9.7% with psilocybin and 23.6% with an antihistamine placebo. In a 2026 extension with 59 adults, heavier drinkers' gains faded after a month.⁸
Treatment-resistant depression, NEJM 2022 (PMID 36322843)	NYSPI, one of 25 sites in the registry record¹	In 233 people, the highest of three doses cut depression scores 6.6 points more than a very low control dose at week 3.⁹
Major depression, JAMA 2023 (PMID 37651119)	NYU was one of 11 sites	In 104 adults, depression scores were 12.3 points lower with psilocybin than with niacin at day 43.¹⁰
Body dysmorphic disorder, J Psychiatr Res 2023 (PMID 37004409)	Sponsored and run by NYSPI	In an open-label pilot, 7 of 12 adults responded by week 12.¹¹
PTSD, J Psychopharmacol 2026 (PMID 40883964)	Mount Sinai site; Yehuda a coauthor	In 22 people, PTSD scores fell an average of 29.9 points by week 4, with no control group.¹²
Clergy, Psychedelic Medicine 2025 (PMID 41869007)	NYU arm with Johns Hopkins	Of 24 clergy who completed both sessions, 96% rated one among the five most spiritually significant experiences of their lives.¹³

Two later trials will shape what comes next. In February 2026, Compass Pathways reported that its second phase 3 trial of COMP360, its synthetic psilocybin, beat a very low control dose by 3.8 points on the MADRS depression scale at week 6, in 581 people with treatment-resistant depression; its first had beaten placebo by 3.6 points. These are company-reported results, not yet peer-reviewed, and Compass expected to finish its FDA application in the fourth quarter of 2026.¹⁴ New York sites, including NYSPI, took part in both.¹ Our guide to psilocybin therapy in NYC explains what an approval would change here.

How to find and screen for a trial in New York

Each study team decides who's eligible. This is what the New York records describe.

Search. Use the list above, or search ClinicalTrials.gov for psilocybin with the location set to New York and the status to "Recruiting."
Check the New York site's own status. A trial can be recruiting overall while its New York site isn't: NYU's site on the Johns Hopkins tobacco trial (NCT05452772) is listed as active, not recruiting.²
Contact the team. Each registry record has a "Contacts and Locations" section. NYU's Center for Psychedelic Medicine lists its open studies on its research page.⁴ Columbia's Depression Evaluation Service asks people interested in its studies to call 646-774-8000.⁶ Mount Sinai's depression study lists its Depression and Anxiety Center, (212) 241-6539.²
Expect several screening visits: a psychiatric interview, medical history, physical exam, ECG and lab tests, plus an MRI safety check for imaging studies. Mount Sinai's trauma study also asks for someone "who will be able to accompany them home and stay the night."²
Don't change your medicines first. The same study says applicants "should not stop, taper, or otherwise change prescribed medications before speaking with the study team."²

Common reasons people are screened out

NYU's alcohol study and Mount Sinai's depression and trauma studies share most of their exclusions:²

Psychosis, mania or bipolar disorder, in you or in a parent, sibling or child.
Active suicidal intent, or a recent medically serious suicide attempt.
Heart disease, arrhythmia or high blood pressure that isn't controlled.
Pregnancy or breastfeeding.
Recent psychedelic use: two of the three exclude anyone who used a classic psychedelic in the past year.
Interacting medicines: Mount Sinai's depression study excludes antipsychotics, serotonergic antidepressants and mood stabilizers, among others.

Most trials take adults 18 and over; several start at 21, and one at NYU takes only healthy adults 65 to 85.¹ Many are randomized, so you may get a placebo instead of psilocybin. Our safety and help page covers risks outside a trial.

How we built this list, and why records go stale

On November 2, 2026, we queried the ClinicalTrials.gov API for psilocybin, psilocin, COMP360, CYB003, RE104 and related terms, kept every study with a New York State site, and removed four text matches that don't give psilocybin. A study counts as recruiting only if it's recruiting overall and its New York site is open or has no site status.¹ Statuses are whatever the sponsor last reported, and some lag:²

Mount Sinai's depression study (NCT06592833) was last updated May 14, 2025, but still says recruiting.
The estimated start dates of three not-yet-recruiting studies have passed: IBS (NCT06760533), stuttering (NCT07296328) and cancer pain (NCT06827054).
The registry gives 347 enrolled for Usona's phase 2 trial (NCT03866174); the JAMA paper reports 104 randomized.¹⁰ NYU's clergy record lists 12; the paper reports 29 randomized across NYU and Johns Hopkins.¹³

If a record looks stale, call the study team. The whole list downloads as CSV or JSON from the link under the records above. MDMA and ketamine studies in the city are on our therapy page, and the Albany bills that would create a medical program are on our bill tracker.

Questions people ask

Is it legal to take psilocybin in a New York clinical trial?

Yes. Researchers giving a Schedule I drug hold a federal research registration under 21 U.S.C. 823, granted after the protocol is reviewed. Outside a study, possessing psilocybin in New York is a class A misdemeanor at minimum.¹⁵

Can I join if I've used mushrooms before?

Sometimes. NYU's alcohol study excludes anyone who used a classic psychedelic in the past year or more than 25 times in their life; Mount Sinai's depression study excludes use in the last 12 months.²

Will I definitely get psilocybin if I enroll?

Not in a randomized trial: NYU's alcohol study compared psilocybin with an antihistamine, and Usona's depression trial with niacin.^{8, 10} Open-label studies, like the Mount Sinai PTSD study, give everyone psilocybin.¹²

Sources

ClinicalTrials.gov API v2, study searches for psilocybin, psilocin, COMP360, CYB003 and RE104, filtered to sites in New York State. U.S. National Library of Medicine, queried November 2, 2026. The full record set is the dataset on this page.
ClinicalTrials.gov study records: NCT06349083, NCT06592833, NCT06899165, NCT05452772, NCT07570654, NCT06796062, NCT06760533, NCT07296328, NCT06827054, NCT03866174, NCT02421263. Retrieved November 2, 2026.
ClinicalTrials.gov NCT06564818 (CYB003, "a Deuterated Psilocin Analog"); Ludbrook G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous RE104: a double-blind, randomized, single ascending dose placebo-controlled study, J Clin Psychopharmacol, 2025;45(5):441-453, PMID 40685873; Bryson N, et al. RE104: synthesis and activity of a novel serotonergic psychedelic prodrug of 4-hydroxy-N,N-diisopropyltryptamine, ACS Chem Neurosci, 2024;15(12):2386-2395, PMID 38758589.
NYU Langone Health establishes Center for Psychedelic Medicine. NYU Langone, February 24, 2021; and the center's research page, retrieved November 2, 2026.
Mount Sinai Health System launches Center for Psychedelic Psychotherapy and Trauma Research. Mount Sinai, January 7, 2021; and Mount Sinai expands psychedelic research center with new facility in Upper Manhattan, September 19, 2024.
Depression Evaluation Service: treating depression and other disorders, modified August 13, 2025; and the service's current studies page, retrieved November 2, 2026. Columbia University Department of Psychiatry.
Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. J Psychopharmacol, 2016;30(12):1165-1180. PMID 27909164. Follow-up: Agin-Liebes GI, et al., J Psychopharmacol, 2020. PMID 31916890.
Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry, 2022;79(10):953-962. PMID 36001306. Extension: Pagni BA, et al., Drug Alcohol Depend, 2026. PMID 42913354.
Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022;387(18):1637-1648. PMID 36322843.
Raison CL, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA, 2023;330(9):843-853. PMID 37651119.
Schneier FR, et al. Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. J Psychiatr Res, 2023;161:364-370. PMID 37004409.
McGowan NM, et al. Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: a nonrandomized open-label clinical trial. J Psychopharmacol, 2026;40(1):139-148. PMID 40883964.
Griffiths RR, et al. Effects of psilocybin on religious and spiritual attitudes and behaviors in clergy from various major world religions. Psychedelic Med, 2025;3(4):172-191. PMID 41869007.
Compass Pathways, Form 8-K on COMP006 and COMP005 results, February 17, 2026; and second quarter 2026 results, Exhibit 99.1, August 5, 2026. U.S. Securities and Exchange Commission.
21 U.S.C. 823(g), registration of researchers using Schedule I substances. Legal Information Institute; and New York Penal Law 220.03, New York State Senate, revision of October 15, 2021.

Which psilocybin clinical trials are recruiting in New York?